Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12615000912583
Ethics application status
Approved
Date submitted
21/07/2015
Date registered
2/09/2015
Date last updated
9/02/2018
Type of registration
Retrospectively registered

Titles & IDs
Public title
Radionuclide therapy using Lutetium-177 prostate specific membrane antigen (PSMA): a pilot study in men with castrate-resistant prostate cancer (LuPSMA trial)
Scientific title
For men with metastatic prostate cancer refractory to hormonal and chemotherapy, what is the efficacy and toxicity of radionuclide therapy with Lutetium-177 PSMA
Secondary ID [1] 287130 0
Nil
Universal Trial Number (UTN)
U1111-1172-4095
Trial acronym
LuPSMA Trial
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prostate Cancer 295668 0
Condition category
Condition code
Cancer 295945 295945 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Targeted delivery of radiotherapy (radionuclide therapy) with intravenous administration of Lutetium-177 radiolabelled to prostate specific membrane antigen (LuPSMA).
- administered activity of 4-8 GBq, dose adjusted according to tumour burden, patient weight and renal function. LuPSMA administered on day 1 of a 6 week cycle.
- post therapy imaging following each administration of LuPSMA with quantitative SPECT/CT with each cycle to determine radiation dose delivered to tumour and normal tissues
- further cycles (up to four) will be given if post-therapy imaging demonstrates sufficient uptake to indicate further benefit. Cycles will be separated by 6 weeks
Intervention code [1] 292381 0
Treatment: Other
Comparator / control treatment
not applicable
Control group
Uncontrolled

Outcomes
Primary outcome [1] 295624 0
Efficacy of therapy as determined by quality of life scores (determined using quality of life questionnaire (EORTC-Q30)
Timepoint [1] 295624 0
3 months following completion of therapy
Primary outcome [2] 295953 0
Efficacy of therapy as determined by pain scores (determined using pain questionnaire EORT-BM22 / BPI-SF)
Timepoint [2] 295953 0
3 months post completion of therapy
Primary outcome [3] 295954 0
Efficacy of therapy as determined as determined by imaging response (bone scan, CT, PSMA and FDG PET/CT) (using PCWG4 criteria)
Timepoint [3] 295954 0
3 months post completion of therapy
Secondary outcome [1] 317016 0
Efficacy of therapy as determined as determined by serum PSA (primart outcome)
Timepoint [1] 317016 0
3 months post completion of therapy
Secondary outcome [2] 317017 0
Toxicity of therapy (primary outcome)
Timepoint [2] 317017 0
- clinical assessment prior to each administration of LuPSMA, 6 weeks and 12 weeks following completion of therapy
- vital signs following each administration of LuPSMA
- blood tests (full blood count, urea and electrolytes, liver function tests) 14 and 28 days after each administration of LuPSMA
- telephone follow-up at 14 and 28 days after each administration of LuPSMA
Secondary outcome [3] 317018 0
Normal tissue and tumour dosimetry expressed in cGy
Timepoint [3] 317018 0
Determined using voxel-based quantitative SPECT/CT imaging for each cycle of LuPSMA therapy
Secondary outcome [4] 317019 0
Progression free survival determined from date of commencement of PSMA therapy
Timepoint [4] 317019 0
During follow-up period
- determined using clinical review (up to 1 year)
Secondary outcome [5] 317020 0
Overall survival
Timepoint [5] 317020 0
During follow-up period
- determined using clinical review (up to 1 year)

Eligibility
Key inclusion criteria
1. Pathologically confirmed prostate adenocarcinoma
2. Castration-resistant metastatic disease
3. Prior treatment with Abiraterone, Enzalutamide or both (unless contraindicated, medically unsuitable or patient refuses)
4. Prior Taxane-based chemotherapy (unless contraindicated, medically unsuitable or patient refuses)
5. Documented prostate cancer progression within last 12 months as defined by radiographic progression (soft tissue disease by RECIST v1.1 criteria OR two or more documented new metastases on a bone scan) OR new pain in an area of radiographically evident disease
6. PSMA PET/CT demonstrating uptake intensity significantly greater than liver at sites of disease
7. Eastern Cooperative Oncology Group (ECOG) Performance Status of <= 2
8. Life expectancy > 12 weeks
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
1. Poor kidney function or kidney obstruction (estimated GFR < 40 ml/min, hydronephrosis)
2. Poor blood counts (platelet count < 75,000 x10^9 /L, neutrophil count < 1.5 x 10^9 /L, or Hb < 9.0 g/dL)
3. Poor liver function (albumin <= 25)
4. FDG PET/CT demonstrating sites of major discordant disease (i.e. FDG + PSMA-)
5. Recent radiotherapy (within 6 weeks) to sole sites of assessable disease
6. Uncontrolled intercurrent illness that would limit compliance with study protocols

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1 / Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
17/09/2015
Actual
28/08/2015
Date of last participant enrolment
Anticipated
Actual
20/06/2017
Date of last data collection
Anticipated
13/12/2017
Actual
8/02/2018
Sample size
Target
30
Accrual to date
Final
50
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 4072 0
Peter MacCallum Cancer Institute - East Melbourne
Recruitment postcode(s) [1] 10020 0
3002 - East Melbourne

Funding & Sponsors
Funding source category [1] 291688 0
Government body
Name [1] 291688 0
Australian Nuclear Science and Technology Organisation (ANSTO)
Country [1] 291688 0
Australia
Primary sponsor type
Hospital
Name
Peter MacCallum Cancer Centre
Address
Locked Bag 1
A'Beckett Street
East Melbourne VIC 3002
Country
Australia
Secondary sponsor category [1] 290399 0
None
Name [1] 290399 0
None
Address [1] 290399 0
None
Country [1] 290399 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 293215 0
Peter MacCallum Cancer Centre Ethics Committee
Ethics committee address [1] 293215 0
Ethics committee country [1] 293215 0
Australia
Date submitted for ethics approval [1] 293215 0
Approval date [1] 293215 0
24/07/2015
Ethics approval number [1] 293215 0
15/66

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 58938 0
A/Prof Michael Hofman
Address 58938 0
Peter MacCallum Cancer Centre
7 St Andrews Place
East Melbourne VIC 3002
Country 58938 0
Australia
Phone 58938 0
+61396561854
Fax 58938 0
Email 58938 0
michael.hofman@petermac.org
Contact person for public queries
Name 58939 0
Michael Hofman
Address 58939 0
Peter MacCallum Cancer Centre
7 St Andrews Place
East Melbourne VIC 3002
Country 58939 0
Australia
Phone 58939 0
+61396561854
Fax 58939 0
Email 58939 0
michael.hofman@petermac.org
Contact person for scientific queries
Name 58940 0
Michael Hofman
Address 58940 0
Peter MacCallum Cancer Centre
7 St Andrews Place
East Melbourne VIC 3002
Country 58940 0
Australia
Phone 58940 0
+61396561854
Fax 58940 0
Email 58940 0
michael.hofman@petermac.org

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseProstate-specific membrane antigen from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer.2017https://dx.doi.org/10.1111/bju.13871
Embase[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.2018https://dx.doi.org/10.1016/S1470-2045%2818%2930198-0
EmbaseDeep learning renal segmentation for fully automated radiation dose estimation in unsealed source therapy.2018https://dx.doi.org/10.3389/fonc.2018.00215
EmbaseMeeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.2018https://dx.doi.org/10.1002/pros.23642
EmbaseEANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).2019https://dx.doi.org/10.1007/s00259-019-04485-3
EmbasePoor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy.2019https://dx.doi.org/10.1016/j.euo.2018.11.007
EmbaseRadioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.2019https://dx.doi.org/10.2214/AJR.18.20845
EmbaseEfficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study.2020https://dx.doi.org/10.1016/j.eururo.2020.05.004
EmbaseLong-term follow-up and outcomes of retreatment in an expanded 50-patient single-center Phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer.2020https://dx.doi.org/10.2967/jnumed.119.236414
EmbaseLooking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.2020https://dx.doi.org/10.1007/s11064-019-02909-y
EmbaseRadiation dosimetry in 177lu-psma-617 therapy using a single posttreatment spect/ct scan: A novel methodology to generate time- And tissue-specific dose factors.2020https://dx.doi.org/10.2967/jnumed.119.233411
EmbaseApplication and Importance of Theranostics in the Diagnosis and Treatment of Cancer.2021https://dx.doi.org/10.1016/j.arcmed.2020.10.016
EmbaseImmune checkpoints, inhibitors and radionuclides in prostate cancer: Promising combinatorial therapy approach.2021https://dx.doi.org/10.3390/ijms22084109
EmbasePSMA: a game changer in the diagnosis and treatment of advanced prostate cancer.2021https://dx.doi.org/10.1007/s12032-021-01537-3
EmbaseRadionuclide Therapy in Prostate Cancer: From Standalone to Combination PSMA Theranostics.2021https://dx.doi.org/10.2967/jnumed.120.243295
Dimensions AINomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study2021https://doi.org/10.1016/s1470-2045(21)00274-6
EmbaseLutetium Lu 177 Vipivotide Tetraxetan: First Approval.2022https://dx.doi.org/10.1007/s40291-022-00594-2
EmbaseProstate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications.2022https://dx.doi.org/10.1016/j.euf.2021.06.006
EmbaseThe History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation.2022https://dx.doi.org/10.2967/JNUMED.121.262997
EmbaseTumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?.2022https://dx.doi.org/10.2967/JNUMED.121.261906
EmbaseUpdate of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends.2022https://dx.doi.org/10.3390/jcm11102738
EmbaseCombined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer.2023https://dx.doi.org/10.3389/fonc.2023.1134884
EmbasePSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study.2023https://dx.doi.org/10.2967/jnumed.122.265242
Dimensions AIInnovation in Radionuclide Therapy for the Treatment of Prostate Cancers: Radiochemical Perspective and Recent Therapeutic Practices2023https://doi.org/10.3390/cancers15123133
N.B. These documents automatically identified may not have been verified by the study sponsor.